$45.76 0.3 0.7%
Last Trade - 4:27pm
| Market Cap | £1.74bn |
| Enterprise Value | £1.18bn |
| Revenue | £622.4m |
| Position in Universe | 1810th / 6416 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | TTM | 2020E | 2021E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|---|
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2020
|
31st Dec 2021
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH). The Company's drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management. The Company's drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. The Company's programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases, and an undisclosed orphan GPCR for central nervous system (CNS) indication(s).
| Last Annual | December 31st, 2018 |
| Last Interim | September 30th, 2019 |
| Incorporated | April 14, 1997 |
| Public Since | July 28, 2000 |
| No. of Shareholders: | 65 |
| No. of Employees: | 194 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Global Select Market |
| Shares in Issue | 50,107,145 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 6154 Nancy Ridge Dr, SAN DIEGO, 92121-3223, United States |
| Web | http://www.arenapharm.com/ |
| Phone | +1 858 4537200 |
| Contact | () |
| Auditors | KPMG LLP |
